Fresh Tracks announces FRTX-02 is potent and selective inhibitor of DYRK1A

Fresh Tracks Therapeutics announced publication of data from preclinical studies of FRTX-02, a potential first-in-class, orally bioavailable DYRK1A inhibitor, in the Journal of Translational Autoimmunity. The paper shows FRTX-02 to be a potent and selective inhibitor of DYRK1A with the potential to restore immune homeostasis by regulating adaptive and innate immune system responses in models of various autoimmune and inflammatory diseases. "We are excited to publish the results from several preclinical studies of FRTX-02 in animal models of psoriasis and atopic dermatitis," commented Monica Luchi, M.D., Chief Medical Officer of Fresh Tracks. "These data provide preclinical characterization of FRTX-02 and evidence supporting its role in modulating chronic inflammatory and autoimmune responses, which helped pave the way for this drug candidate to enter a Phase 1 clinical trial in 2022. FRTX-02, to our knowledge, is the first and only clinical-stage, oral DYRK1A inhibitor being developed for patients with autoimmune diseases, and we look forward to reporting topline results from Part 1 of the current Phase 1 study with FRTX-02 by the end of this quarter."